Page last updated: 2024-10-24

positive regulation of transcytosis

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of transcytosis. [GO_REF:0000058, GOC:TermGenie, PMID:9664076]

Positive regulation of transcytosis is a complex biological process that involves the coordinated movement of molecules across cellular membranes. This process plays a crucial role in a wide range of cellular functions, including cell signaling, nutrient uptake, and waste removal. Transcytosis involves the internalization of molecules into vesicles, followed by their transport across the cell and subsequent release on the other side. Positive regulation of transcytosis refers to any mechanism that enhances or accelerates this process.

Several key factors are involved in the positive regulation of transcytosis:

1. **Signaling pathways:** Specific signaling molecules, such as growth factors and cytokines, can activate intracellular pathways that stimulate transcytosis. These pathways often involve the phosphorylation of key regulatory proteins.

2. **Cytoskeletal rearrangements:** Transcytosis requires the coordinated movement of vesicles through the cytoplasm. This movement is facilitated by the cytoskeleton, a network of protein filaments that provide structural support and act as tracks for vesicle transport. Actin filaments are particularly important for the movement of vesicles within the cell, while microtubules play a role in long-distance transport. Positive regulation of transcytosis can involve modifications to the cytoskeleton, such as changes in the organization or dynamics of these filaments.

3. **Vesicle formation and trafficking:** The formation and trafficking of vesicles are critical steps in transcytosis. The process begins with the invagination of the plasma membrane to form endocytic vesicles. These vesicles then travel through the cell, often passing through the endosome compartment. Eventually, they fuse with the plasma membrane on the opposite side of the cell, releasing their cargo into the extracellular space. Positive regulation of transcytosis can involve mechanisms that enhance vesicle formation, increase the rate of vesicle transport, or promote fusion events.

4. **Cargo sorting and selection:** The specific molecules that undergo transcytosis must be sorted and selected from the pool of available molecules at the plasma membrane. This process is often mediated by specific receptors that bind to the cargo molecules and initiate their internalization into vesicles. Positive regulation of transcytosis can involve the upregulation of these receptors or changes in their affinity for cargo.

5. **Regulation of motor proteins:** Vesicle movement is driven by motor proteins that bind to the cytoskeleton and move vesicles along these tracks. Positive regulation of transcytosis can involve changes in the expression or activity of these motor proteins, leading to faster or more efficient vesicle transport.

In summary, the positive regulation of transcytosis is a multi-faceted process that involves the coordinated action of numerous cellular components. Understanding the mechanisms that regulate this process is important for understanding various cellular functions and developing therapies for diseases that involve dysregulation of transcytosis.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Platelet-activating factor receptorA mammalian-type platelet-activating factor receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25105]Homo sapiens (human)

Compounds (37)

CompoundDefinitionClassesRoles
brotizolambrotizolam: structureorganic molecular entity
cilostamidecilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structurequinolines
clotrimazoleconazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes
antiinfective agent;
environmental contaminant;
xenobiotic
dephostatindephostatin: from Streptomyces sp. MJ742-NF5; structure given in first source
juglonejuglone : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogen at position 5 has been replaced by a hydroxy group. A plant-derived 1,4-naphthoquinone with confirmed antibacterial and antitumor activities.

juglone: structure
hydroxy-1,4-naphthoquinonegeroprotector;
herbicide;
reactive oxygen species generator
loratadineloratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.

Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide
anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
mesalaminemesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols
non-steroidal anti-inflammatory drug
etoposide phosphate
nifedipineNifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.C-nitro compound;
dihydropyridine;
methyl ester
calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
1,2,5,8-tetrahydroxy anthraquinone1,2,5,8-tetrahydroxy anthraquinone: structure in first source

quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions.
tetrahydroxyanthraquinoneEC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
purpurinpurpurin : A trihydroxyanthraquinone derived from anthracene by substitution with oxo groups at C-9 and C-10 and with hydroxy groups at C-1, C-2 and C-4.

purpurin: from Rubiaceae plants; structure in first source
trihydroxyanthraquinonebiological pigment;
histological dye;
plant metabolite
suramin sodiumsuramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
lithocholic acidlithocholate : A bile acid anion that is the conjugate base of lithocholic acid.

lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.

Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.
bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid
geroprotector;
human metabolite;
mouse metabolite
chrysophanic acidchrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260

chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.
dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
ethidium bromideorganic bromide saltgeroprotector;
intercalator;
trypanocidal drug
daunorubicinanthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.

daunorubicin : A natural product found in Actinomadura roseola.

Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones
antineoplastic agent;
bacterial metabolite
sch 37370N-acetyldesloratadine: dual antagonist of platelet-activating factor and histamine
ro 24-4736Ro 24-4736: structure given in first source; platelet activating factor antagonist
daunorubicin hydrochlorideanthracycline
web 2086WEB 2086: structure given in first source; PAF antagonistorganonitrogen heterocyclic compound;
organosulfur heterocyclic compound
paceinorcein : A variable mixture of several compounds isolated from lichens, the eight most abundant being alpha-aminoorcein, alpha-hydroxyorcein, beta-aminoorcein, gamma-aminoorcein, beta-hydroxyorcein, gamma-hydroxyorcein, beta-aminoorceimine and beta-aminoorceimine (all are phenoxazine-based). It is used for the demonstration of elastic fibres as well as to stain the rough endoplasmic reticulum of hepatitis B infected liver cells.

pacein : A member of the class of benzofurans that is dibenzo[b,d]furan-3,7-dione bearing two methyl substituents at positions 1 and 9 as well as two 2,4-dihydroxy-6-methylanilino substituents at positions 2 and 8.

PAcein: structure
cv 3988CV 3988: platelet activating factor antagonist; structure given in first source
1-hexadecyl-2-acetyl-glycero-3-phosphocholine2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.

Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.
2-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
mk 287MK 287: RN given refers to the trans-(-)-isomer L-680573; L-680574 is an optical enantiomer; L-668750 is the racemic mixture; structure given in first source
rupatadinerupatadine: structure given in first source; RN given refers to trihydrochloridebenzocycloheptapyridine
sdz 64-412SDZ 64-412: structure given in first source; PAF antagonist
doxorubicin hydrochlorideanthracycline
2-thiophenecarboxylic acid 2-(1,3-dioxo-2-isoindolyl)ethyl esterphthalimides
suramin sodiumsuramin(6-) : An organosulfate oxoanion that is the hexanion of suramin resulting from the deprotonation of the six sulfo groups; major species at pH 7.3.organosulfate oxoanion
gw-5074
nf 449
ginkgolide b
ro 24-0238Ro 24-0238: PAF antagonist
l 652731
lexipafantlexipafant: an imidazolyl derivative which forms part of a fused heterocyclic system
abt 299ABT 299: converted in vivo to A-85783.0; a platelet activating factor antagonist; structure in first source
orvepitant